Insulet Corporation Stock News

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to recognize National Diabetes Awareness Month and World Diabetes Day with a series of activities in November. “People with diabetes must make dozens of decisions every day to manage their con...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the full market release of the Omnipod 5 App for iPhone® in the U.S. Now available to download for free on the Apple App Store, the App allows users to fully control their Omnipod 5 Automated Insuli...

SAN FRANCISCO , Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes.   The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes and reduce sti...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference c...

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period.

The highly specialized medical device maker earns an important nod from a top regulator. A label expansion could potentially reach a market of 6 million people.

Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later in the week.

Insulet got a key FDA approval for an insulin delivery system.